Please ensure Javascript is enabled for purposes of website accessibility

Why Lumber Liquidators Holdings,, and La Jolla Pharmaceutical Slumped Today

By Dan Caplinger - Feb 12, 2018 at 4:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The market soared, but these stocks got left behind. Find out why.

Monday saw another explosive move for the stock market -- but this time into positive territory. Some major benchmarks were up almost 2% as investors continued to bet on the sustained momentum of the 9-year-old bull market. Yet even though market participants have generally been upbeat about the prospects for the economy at large, they've still identified some pockets of concern that hurt certain individual stocks. Lumber Liquidators Holdings (LL 4.05%), (STMP), and La Jolla Pharmaceutical (LJPC -2.19%) were among the worst performers on the day. Below, we'll look more closely at these stocks to tell you why they did so poorly.

Lumber Liquidators gets sawed down to size

Shares of Lumber Liquidators Holdings dropped 9% after the flooring specialist got a downgrade from analysts at Wedbush. The analyst company lowered its rating on Lumber Liquidators from outperform to neutral, cutting its price target on the stock from $39 per share to $28. Wedbush is concerned that the flooring retailer has already gotten all of the growth momentum from paying greater attention to selling to professional contractors and performing installations over the past year, and future growth could be harder to come by. Meanwhile, if the home improvement specialist has to cut prices in order to compete with industry rivals, then Lumber Liquidators could see even greater disruptions in the near future.

Room with modest amount of furniture and wood flooring prominently displayed.

Image source: Lumber Liquidators. falls despite takeover speculation stock was down 5% even though some of those following the online postage specialist believe that it could be a takeover target. Analyst company B Riley reiterated its buy rating and price target of $250 per share on, asserting that the postage company could either team up with established carriers or get bought out by e-commerce giants. Yet the fear is that e-commerce specialists will simply reinvent shipping on their own, bypassing traditional carriers and the companies like that provide related services. It's too early to be sure, but for now, shareholders are nervous about's ability to hold its own in a more competitive environment.

La Jolla completes the trilogy

Finally, shares of La Jolla Pharmaceutical dropped 13%. The pharma company got a downgrade from analysts at Jefferies, who cut their rating from buy to underperform and reducing their price target from $40 per share to $29. According to Jefferies, La Jolla could have trouble with its blood-pressure medication Giapreza, especially if the number of patients starting to use the drug proves to be less than the company had initially hoped. Investors were pleased late last year when the FDA approved Giapreza somewhat early, but they'll have to wait until later this spring to see whether analysts' fears are justified.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Lumber Liquidators Holdings, Inc. Stock Quote
Lumber Liquidators Holdings, Inc.
$9.75 (4.05%) $0.38 Inc. Stock Quote Inc.
La Jolla Pharmaceutical Company Stock Quote
La Jolla Pharmaceutical Company
$3.12 (-2.19%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.